Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.

PMID:
16923923
2.

Experience with tenofovir disoproxil fumarate for antiretroviral therapy.

Stephan C.

Expert Opin Pharmacother. 2008 May;9(7):1197-209. doi: 10.1517/14656566.9.7.1197. Review.

PMID:
18422476
3.

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.

Fung HB, Stone EA, Piacenti FJ.

Clin Ther. 2002 Oct;24(10):1515-48. Review.

PMID:
12462284
4.

Review of tenofovir use in HIV-infected children.

Aurpibul L, Puthanakit T.

Pediatr Infect Dis J. 2015 Apr;34(4):383-91. doi: 10.1097/INF.0000000000000571. Review.

PMID:
25247583
5.

Emtricitabine/tenofovir disoproxil fumarate.

[No authors listed]

Drugs R D. 2004;5(3):160-1. Review.

PMID:
15139777
7.

Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?

Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM.

HIV Med. 2009 Aug;10(7):397-406. doi: 10.1111/j.1468-1293.2009.00709.x. Epub 2009 May 12. Review.

8.

Pharmacogenetics of tenofovir treatment.

Rodriguez-Novoa S, Labarga P, Soriano V.

Pharmacogenomics. 2009 Oct;10(10):1675-85. doi: 10.2217/pgs.09.115. Review.

PMID:
19842939
9.

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Ray AS, Fordyce MW, Hitchcock MJ.

Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Review.

10.

Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.

Hemkens LG, Ewald H, Santini-Oliveira M, Bühler JE, Vuichard D, Schandelmaier S, Stöckle M, Briel M, Bucher HC.

HIV Clin Trials. 2015 Oct;16(5):178-89. doi: 10.1179/1945577115Y.0000000004. Review.

PMID:
26395328
11.

Tenofovir Alafenamide: A Review of Its Use in the Treatment of HIV-1 Infection.

Gibson AK, Shah BM, Nambiar PH, Schafer JJ.

Ann Pharmacother. 2016 Jul 26. pii: 1060028016660812. [Epub ahead of print] Review.

PMID:
27465879
12.

Antiretroviral Treatment Efficacy and Safety in Older HIV-Infected Adults.

Jourjy J, Dahl K, Huesgen E.

Pharmacotherapy. 2015 Dec;35(12):1140-51. doi: 10.1002/phar.1670. Review.

PMID:
26684554
13.

Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B.

Lou L.

J Clin Transl Hepatol. 2013 Sep;1(1):33-8. doi: 10.14218/JCTH.2013.004XX. Epub 2013 Sep 15. Review.

14.

Unresolved antiretroviral treatment management issues in HIV-infected children.

Heidari S, Mofenson LM, Hobbs CV, Cotton MF, Marlink R, Katabira E.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):161-9. doi: 10.1097/QAI.0b013e3182427029. Review.

15.

Skeletal health in adults with HIV infection.

Bolland MJ, Grey A, Reid IR.

Lancet Diabetes Endocrinol. 2015 Jan;3(1):63-74. doi: 10.1016/S2213-8587(13)70181-5. Epub 2014 Feb 26. Review.

PMID:
24731663
16.

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

Achhra AC, Nugent M, Mocroft A, Ryom L, Wyatt CM.

Curr HIV/AIDS Rep. 2016 Jun;13(3):149-57. doi: 10.1007/s11904-016-0315-y. Review.

PMID:
27130284
17.

The role of tenofovir alafenamide in future HIV management.

Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon P, Pourcher-Martinez V, Di Perri G.

HIV Med. 2016 May;17 Suppl 2:4-16. doi: 10.1111/hiv.12401. Review.

PMID:
26952360
18.

Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Neely MN, Rakhmanina NY.

Clin Pharmacokinet. 2011 Mar;50(3):143-89. doi: 10.2165/11539260-000000000-00000. Review.

PMID:
21294595
19.

An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

De Clercq E.

Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 2. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk